VEGFA and pneumonitis: Usui et al. demonstrated a higher incidence of pneumonitis in patients with colorectal cancer who were treated with conventional cytotoxic chemotherapeutic drugs plus bevacizumab (BEV), another VEGF inhibitor, than in those who did not receive BEV [21].